Ruxolitinib Cream for the Treatment of Patients With Alopecia Areata: A 2-Part, Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study.
There are currently no universally effective or FDA-approved treatments for alopecia areata (AA). Oral ruxolitinib has shown efficacy in extensive AA. Ruxolitinib cream would potentially avoid systemic side effects. To assess the efficacy and safety of 1.5% ruxolitinib cream in patients with AA who had ≥25% hair loss by Severity of Alopecia Tool (SALT) score. This was a 2-part study. Part A was an open-label, 24-week study of 1.5% ruxolitinib cream in patients with 25%-99% hair loss followed by a 24-week extension period. Part B was a double-blind, vehicle-controlled, 24-week study of 1.5% ruxolitinib cream in patients with 25%-100% hair loss, followed by a crossover to ruxolitinib cream in the vehicle group for 24 weeks, and additional treatment time for the ruxolitinib cream group. Although Part A results suggested potential efficacy of 1.5% ruxolitinib cream, there was no significant difference in hair regrowth by SALT50 scores between patients on 1.5% ruxolitinib cream and vehicle in Part B. There were no significant safety issues with 1.5% ruxolitinib cream. Single strength of ruxolitinib cream CONCLUSIONS: 1.5% ruxolitinib cream did not demonstrate a significant effect in patients with AA.